8-K: Amedisys Reports Mixed Fourth Quarter and Year-End 2024 Results Amidst Pending UnitedHealth Group Merger

Amedisys reports a net loss for Q4 2024, impacted by merger-related expenses and impairment charges, while annual net income improves compared to the previous year.

Summary

• Amedisys reported its financial results for the three-month period and year ended December 31, 2024.
• Net service revenue for the fourth quarter increased by $27.3 million to $598.1 million, compared to $570.8 million in 2023.
• The company reported a net loss attributable to Amedisys, Inc. of $20.4 million for the quarter, which includes $17.4 million in merger-related expenses and a $48.4 million non-cash impairment charge.
• This compares to a net income of $19.3 million in the same period of 2023, which included $11.5 million in merger-related expenses.
• Adjusted EBITDA for the quarter was $54.6 million, compared to $56.7 million in 2023.
• Adjusted net income attributable to Amedisys, Inc. was $32.0 million, compared to $30.8 million in 2023.
• For the year ended December 31, 2024, net service revenue increased by $111.9 million to $2,348.3 million, compared to $2,236.4 million in 2023.
• Net income attributable to Amedisys, Inc. was $43.2 million for the year, which includes $66.6 million in merger-related expenses and a $48.4 million non-cash impairment charge.
• This compares to a net loss of $9.7 million in 2023, which included $142.7 million in merger-related expenses.
• Adjusted EBITDA for the year was $245.8 million, compared to $247.0 million in 2023.
• Adjusted net income attributable to Amedisys, Inc. was $142.7 million, compared to $140.6 million in 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, the net loss and pending merger create uncertainty. The company is performing reasonably well, but the future is unclear.

Positives

• Net service revenue increased for both the quarter and the year.
• Adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. per diluted share increased for both the quarter and the year.
• Home Health same store admissions increased by 8% in Q4 2024.
• Hospice same store average daily census (ADC) increased by 0.5% in Q4 2024.
• High Acuity Care admissions increased by 29% in Q4 2024.
• Amedisys' January 2025 STARS score was 4.18, with 88% of care centers at 4+ Stars.
• Free cash flow increased from $107.9 million to $180.7 million year over year.

Negatives

• The company reported a net loss attributable to Amedisys, Inc. of $20.4 million for the quarter, impacted by merger-related expenses and a non-cash impairment charge.
• Adjusted EBITDA decreased slightly for both the quarter and the year.
• Gross margin percentage decreased from 44.0% to 42.7% for the quarter and from 44.6% to 43.7% for the year.
• Home Health gross margin decreased from 42.5% to 40.4% for the quarter and from 43.3% to 41.7% for the year.
• Hospice gross margin decreased from 47.9% to 47.6% for the quarter and from 48.6% to 48.3% for the year.

Risks

• The pending merger with UnitedHealth Group introduces disruption to patient, payor, provider, referral source, supplier, management, and employee relationships.
• The merger agreement could be terminated, or the transaction may not be completed on anticipated terms or by the outside date.
• Necessary regulatory approvals for the merger may be delayed, not obtained, or obtained with unanticipated conditions.
• The company faces the risk of litigation or regulatory action related to the proposed merger, including the action by the Department of Justice to block the merger.
• Changes in Medicare and other medical payment levels could impact financial results.
• Staffing shortages driven by the competitive labor market pose a challenge.
• The company's ability to integrate, manage, and keep its information systems secure is a risk factor.

Future Outlook

Due to the pending merger with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the fourth quarter and year end results.

Industry Context

The home health and hospice industry is facing increasing regulatory scrutiny and reimbursement pressures, as well as rising labor costs. Amedisys' results reflect these challenges, particularly in the decline in EBITDA margin. The pending merger with UnitedHealth Group suggests a strategic move to navigate these industry headwinds and capitalize on potential synergies.

Comparison to Industry Standards

• Amedisys' Home Health STARS rating of 4.18 is competitive, with 88% of care centers at 4+ Stars.
• The company's hospice quality metrics are reported as outperforming the industry average in all hospice item set (HIS) categories.
• Visiting clinician cost per visit in Home Health was $110.93, which should be compared to similar companies like LHC Group (part of Optum) and Enhabit to assess cost efficiency.
• Revenue per day in Hospice was $179.02, which is a key metric to benchmark against competitors like Chemed (Vitas Healthcare) and National Healthcare Corporation.

Legal Proceedings

• The document mentions the risk of litigation or regulatory action related to the proposed merger, including the action by the Department of Justice to block the merger.

Stakeholder Impact

• Shareholders face uncertainty due to the pending merger and its potential impact on the company's future.
• Employees may experience disruption and uncertainty related to the merger and potential changes in the organization.
• Patients could be affected by changes in care delivery models or service offerings resulting from the merger.
• Referral sources may need to adjust to new relationships or processes following the merger.

Key Dates